A Phase 1 interventional study of HLX319 and EU-Phesgo® in HER2 + Breast Cancer, sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Breast Neoplasms by Fosun Pharma — 9 open to participants now, 10 under way, 4 of them phase 3. Breast Neoplasms · Fosun Pharma.
Among the 13 studies in Breast Neoplasms by Fosun Pharma, this one is the 6th largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 1, and was the 12th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →9 of the 13 studies in Breast Neoplasms by Fosun Pharma are open now, in 1 country. Recruiting first, the newest first:
Shanghai Henlius Biotech · Sites in China
Ages 18+
Shanghai Henlius Biotech · Sites in China
Ages 18+
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18–75
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Shanghai Henlius Biotech
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 5
First in 2016; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 180 across the 13 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Henlius Biotech, one of the names counted as Fosun Pharma. Under that name alone:
Shanghai Henlius Biotech is the lead sponsor of 133 studies on the registry; 57 are open to participants now.
4 of the studies in Breast Neoplasms by Fosun Pharma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07459738Shanghai Henlius BiotechA Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer | 2026-12-30 |
| NCT07601620Shanghai Henlius BiotechA Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer | 2027-04-23 |
| NCT07487519Shanghai Henlius BiotechPhase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. | 2027-05-15 |
| NCT06832202Shanghai Henlius BiotechA Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Breast Neoplasms by Fosun Pharma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
This is a randomized, double-blind, parallel-controlled, multi-center Phase I equivalence study to compare the similarity in PK profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer with a primary tumor > 2 cm or nodes-positive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
Drug: HLX319
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
Drug: EU-Phesgo®
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.
Peak concentration (Cmax)
Peak concentration after a single drug administration in Cycle 1.
Time frame: up to 180 days
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
Time frame: up to 180 days
Steady-state peak concentration (Cmax,ss)
The steady-state peak concentration after multiple doses administration in Cycle 4.
Time frame: up to 180 days
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
Time frame: up to 180 days
Trough concentration (Ctrough)
Trough concentration after a single dose administration
Time frame: up to 180 days
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
Time frame: up to 180 days
Percentage of extrapolated area in the total AUC (%AUCex)
Percentage of extrapolated area in the total AUC after a single dose administration
Time frame: up to 180 days
Time to peak concentration (Tmax)
time to peak concentration after a single dose administration
Time frame: up to 180 days
Elimination half-life (T1/2)
elimination half-life after a single dose administration
Time frame: up to 180 days
Total clearance (CL/F)
total clearance after a single dose administration
Time frame: up to 180 days
Terminal phase distribution volume (Vz/F)
terminal phase distribution volume after a single dose administration
Time frame: up to 180 days
Mean residence time (MRT)
mean residence time after a single dose administration
Time frame: up to 180 days
Steady-state trough concentration (Ctrough,ss)
steady-state trough concentration after multiple doses administration in Cycle 4
Time frame: up to 180 days
Average steady-state concentration (Caverage,ss)
average steady-state concentration after multiple doses administration in Cycle 4
Time frame: up to 180 days
Steady-state time to peak concentration (Tmax,ss)
steady-state time to peak concentration after multiple doses administration in Cycle 4
Time frame: up to 180 days
Elimination half-life (T1/2,ss)
elimination half-life after multiple doses administration in Cycle 4
Time frame: up to 180 days
Steady-state volume of distribution (Vss/F)
steady-state volume of distribution after multiple doses administration in Cycle 4
Time frame: up to 180 days
Steady-state total clearance (CLss/F)
steady-state total clearance after multiple doses administration in Cycle 4
Time frame: up to 180 days
accumulation ratio based on Cmax (RCmax)
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
Time frame: up to 180 days
Accumulation ratio based on AUC (RAUC)
accumulation ratio based on AUC after multiple doses administration in Cycle 4
Time frame: up to 180 days
The total pathological complete response (tpCR) rate assessed by the investigator
Time frame: up to 180 days
Breast pathologic complete response (bpCR) rate assessed by the investigator
Time frame: up to 180 days
Objective response rate (ORR) assessed by the investigator
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
Time frame: up to 180 days
Incidence and severity of adverse events (AEs)
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
Time frame: up to 180 days
Number of participants with abnormal vital signs
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
Time frame: up to 180 days
Number of participants with abnormal physical examination findings
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
Time frame: up to 180 days
Number of participants with abnormal Laboratory tests results
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
Time frame: up to 180 days
Number of participants with abnormal 12-lead ECG readings
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
Time frame: up to 180 days
Positivity rates of anti-drug antibodies (ADA)
Time frame: up to 180 days
Positivity rates of neutralizing antibodies (NAb)
Time frame: up to 180 days
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Apr 2027, 9 months later.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 9 months is below that.
Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab